Bliss GVS Pharma Ltd Share Price Today

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 100% at ₹1/Share	08-Jul-2026	08-Jul-2026
DividendsInterim Dividend of 50% at ₹0.5/Share	18-Feb-2026	18-Feb-2026
DividendsFinal Dividend of 50% at ₹0.5/Share	24-Jul-2025	24-Jul-2025

Mutual Fund Holder	Aug 26 Shares held	Sep 26 Shares held
Motilal Oswal BSE Healthcare ETF	1.80 k	1.83 k (2%)
Bandhan BSE Healthcare Index Fund - Regular Plan - Growth	843	865 (2.61%)

Sanjay Ahuja

1 Oct • 12:45 PM · SEBI-Registered Analyst

ANUPAM RASAYAN ACQUIRES STAKE IN BLISS GVS PHARMA

Speciality chemicals manufacturer

ANURAS

has completed the acquisition of a 48.2 percent controlling stake in Bliss GVS Pharma for a total acquisition outlay of Rs 1,750 crore, marking it's third strategic inorganic transaction, as the Surat-based company expands into finished pharmaceutical formulations. Bliss GVS is a branded formulations company with more than 150 brands across therapeutic segments and having six manufacturing facilities across Maharashtra. This acquisition will strengthen Anupam Rasayan's presence in finished pharmaceutical formulations and give expertise in key starting materials, intermediates as well as specialty chemicals. The company has reported a sales growth of 24% CAGR in the last 5 years, and with such new acquisitions, it will improve the company's revenue in the coming years.

Saurab Jain

29 Sep • 8:56 AM · SEBI-Registered Analyst

Bliss GVS Pharma Hits Fresh ATH After ₹728 Breakout

Bliss GVS Pharma hits a fresh all-time high at ₹737.65 after breaking ₹728 resistance. The stock has gained around 347% in CY2026, reflecting strong momentum. Bliss GVS Pharma Ltd. (

BLISSGVS

) hits a fresh all-time high at ₹737.65 after breaking ₹728 resistance. The stock has gained around 347% in CY2026, reflecting strong momentum. Bliss GVS Pharma Ltd. remained in the spotlight after the stock hit the 5% upper circuit and closed at ₹737.65, gaining 4.68% or ₹32.95 in the session on 28 Sept 2026. The stock also marked a fresh all-time high, extending its price momentum. From a technical perspective, the stock continues to display a strongly bullish trend. After a period of decent consolidation near the top, BLISSGVS broke above the key resistance zone of ₹728 and closed above that level, marking a notable breakout. The stock's price performance in CY2026 has been particularly striking, with gains of around 347% so far. Bliss GVS Pharma operates globally across 60+ countries and has a strong presence in pharmaceutical formulations, particularly suppositories and pessaries. With the stock at ₹737.65, above its previous ₹728 resistance and at a fresh all-time high, BLISSGVS is currently witnessing a strong bull run. The breakout above ₹728 came after a period of consolidation, adding significance to the latest price move. The price action remains the key feature of the stock's current market setup. Disclosure: I do not hold any position or have any financial interest in the mentioned stock.

THREETREND RESEARCH

22 Jun • 5:59 AM · SEBI-Registered Analyst

NETWEB

Stocks up more than +100% in last 1 year: Swan Defence: +978% Cupid: +852% Sterlite Tech.: +518% Sigma Advanced System: +515% Modern Insulator: +462% V-Marc India: +445% MTAR Technologie: +388% Midwest Gold: +387% CIAN Agro: +337% Venus Remedies: +301% Bajaj Consumer: +269% Bliss GVS Pharma: +251% IDream Film: +248% GE Power: +246% Belding India: +229% Ather Energy: +203% Stallion India: +200% SBC Exports: +200% Thangamayil Jew: +190% Netweb Tech.: +187% Acutaas Chemical: +187% John Cockerill: +177% Onix Solar: +171% Syrma SGS Tech: +163% Concord Control: +162% HFCL: +156% Rossell Techsys: +156% Rashi Peripheral: +153% Senores Pharma: +153% Shanti Educat: +149% Aeroflex: +148% TD Power : +147% Knowledge Marine: +146% Yash Highvoltage: +146% Silver Touch: +143% Kwality Pharma: +141% Grand Oak Canyon: +139% Belrise Industri: +136% Kirloskar Oil: +135% GE Vernova T&D: +135% Jayaswal Neco: +132% Prec. Wires: +131% Quality Power: +131% Vodafone Idea: +127% DEE Development: +127% Kesar India: +126% SML Mahindra: +125% Apollo Micro: +123% KS Smart Technlogies: +122% Sansera Engine: +122% Mobavenue AI Tech: +120% Adani Power: +119% Aimtron: +117% Laurus Labs: +117% Black Box: +114% AGI Infra: +110% Avalon Tech: +109% Apar Inds: +106% Hindustan Copper: +106% Wheels India: +104% Nat Aluminium: +104% United Foodbrands: +103% Rishabh Instru: +103% Stylam Industrie: +102% Gabriel India: +102% Diamond Power: +102% Prime Focus: +102% Indian Metals: +101% Rategain Travel: +100% 26% of total Universe delivered more than 25% returns This is for MCAP > 2000 Cr Broader markets remain strong lately, real alpha is coming from stock selection

Ankush

3 Jun • 9:15 AM · SEBI-Registered Analyst

BLISSGVS

Bliss GVS Pharma are likely to remain in focus on June 3 after the company announced that it has received an Inspection Closure Report from the World Health Organization (WHO), Geneva, for its manufacturing facility in Palghar, Maharashtra. The report confirmed that the facility complies with the Good Manufacturing Practices (GMP) standards prescribed by the WHO, reinforcing the company's commitment to global quality and manufacturing excellence. In the previous trading session, Bliss GVS Pharma shares ended at Rs 434.75, gaining Rs 32.75 or 8.15 percent. The stock touched a 52-week high of Rs 442.20 on June 2, 2026, and a 52-week low of Rs 118.35 on November 10, 2025. At the current market price, the stock is trading 1.68 percent below its 52-week high and has surged 267.34 percent from its 52-week low.

Naveen Kumar

26 May • 2:50 PM · SEBI-Registered Analyst

BLISSGVS

Bliss GVS Pharma Limited is undergoing a major ownership transition, as Anupam Rasayan India Limited has moved to acquire a controlling stake. Anupam Rasayan has signed an agreement to purchase 43.30% of Bliss GVS from existing promoters and select public shareholders at ₹299 per share. Triggering SEBI’s takeover regulations, the acquirer is now launching a mandatory open offer to purchase an additional 26% of the company’s expanded voting share capital from public shareholders at the same ₹299 price. For investors, this acquisition signals a significant shift in corporate leadership, with the acquirer set to become the new promoter and gain full control. While the offer provides an immediate exit opportunity at a fixed cash price, it also marks the end of the current promoter group's tenure. Since the acquirer has stated it has no intention to delist, the company will likely continue its operations under new strategic management.

Ujvin Nevatia

24 May • 11:37 PM · SEBI-Registered Analyst

Anupam Rasayan Expands Pharma Presence With ₹1,369 Crore Bliss GVS Deal

ANURAS

will acquire up to a 43% stake in Bliss GVS Pharma for around ₹1,369 crore. The acquisition marks a major diversification step for Anupam Rasayan, which has primarily operated in specialty chemicals and custom synthesis. The deal strengthens the company’s presence in the pharmaceutical sector, particularly in formulations and women’s healthcare products where Bliss GVS has an established footprint. The acquisition also reflects increasing consolidation across pharma and specialty chemical industries as companies look to expand capabilities and reduce dependence on single business segments. The move is expected to improve Anupam Rasayan’s access to regulated pharmaceutical markets and create broader revenue diversification opportunities. Industry Outlook India’s pharmaceutical and specialty chemical sectors are increasingly converging through acquisitions and strategic partnerships. Companies are focusing on diversification, export expansion, and higher-value product categories to strengthen long-term growth. At the same time, the pharma sector continues benefiting from rising global healthcare demand and supply-chain diversification away from China. However, regulatory scrutiny, pricing pressure, and integration risks remain key challenges for companies pursuing aggressive acquisitions. The deal also highlights a broader trend where Indian chemical and pharma firms are moving toward integrated business models to improve margins and reduce cyclical exposure. Overall, the sector outlook remains positive due to strong export potential and healthcare demand, but successful integration and operational efficiency will remain critical for sustaining profitability after large acquisitions. Source: NDTV Profit No Recommendations

Bliss GVS Pharma Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Bliss GVS Pharma Ltd. 👋

Expert Opinions

News & Events

Frequently Asked Questions

What is the share price of Bliss GVS Pharma Ltd.?

What is the market cap of Bliss GVS Pharma Ltd.?

Should I buy Bliss GVS Pharma Ltd. stock now?

What is the 52 week high and low of Bliss GVS Pharma Ltd.?

Is the Bliss GVS Pharma Ltd. stock good to buy?

Is Bliss GVS Pharma Ltd. a good buy for the long term?

Is Bliss GVS Pharma Ltd. overvalued or undervalued?

What is the PE and PB ratio of Bliss GVS Pharma Ltd.?